These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28797731)

  • 1. Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics.
    Lieberman PL; Jones I; Rajwanshi R; Rosén K; Umetsu DT
    J Allergy Clin Immunol; 2017 Dec; 140(6):1734-1736.e4. PubMed ID: 28797731
    [No Abstract]   [Full Text] [Related]  

  • 2. Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study.
    Lieberman PL; Umetsu DT; Carrigan GJ; Rahmaoui A
    J Allergy Clin Immunol; 2016 Sep; 138(3):913-915.e2. PubMed ID: 27236498
    [No Abstract]   [Full Text] [Related]  

  • 3. Omalizumab-induced triphasic anaphylaxis in a patient with chronic spontaneous urticaria.
    Gönül M; Özenergün Bittacı A; Ergin C
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e135-e136. PubMed ID: 26446412
    [No Abstract]   [Full Text] [Related]  

  • 4. Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate.
    Perino E; Freymond N; Devouassoux G; Nicolas JF; Berard F
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):664-666. PubMed ID: 29481891
    [No Abstract]   [Full Text] [Related]  

  • 5. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.
    Limb SL; Starke PR; Lee CE; Chowdhury BA
    J Allergy Clin Immunol; 2007 Dec; 120(6):1378-81. PubMed ID: 17936893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.
    Broesby-Olsen S; Vestergaard H; Mortz CG; Jensen B; Havelund T; Hermann AP; Siebenhaar F; Møller MB; Kristensen TK; Bindslev-Jensen C;
    Allergy; 2018 Jan; 73(1):230-238. PubMed ID: 28662309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis.
    Baker DL; Nakamura GR; Lowman HB; Fischer SK
    AAPS J; 2016 Jan; 18(1):115-23. PubMed ID: 26340860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of an anaphylactoid reaction to omalizumab.
    Dreyfus DH; Randolph CC
    Ann Allergy Asthma Immunol; 2006 Apr; 96(4):624-7. PubMed ID: 16680936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect?
    Konstantinou GN; Chioti AG; Daniilidis M
    Eur Ann Allergy Clin Immunol; 2016 Sep; 48(5):205-7. PubMed ID: 27608479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
    Ertaş R; Özyurt K; Yıldız S; Ulaş Y; Turasan A; Avcı A
    Iran J Allergy Asthma Immunol; 2016 Feb; 15(1):82-6. PubMed ID: 26996116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.
    Cox L; Platts-Mills TA; Finegold I; Schwartz LB; Simons FE; Wallace DV; ;
    J Allergy Clin Immunol; 2007 Dec; 120(6):1373-7. PubMed ID: 17996286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients.
    Ghazanfar MN; Sand C; Thomsen SF
    Br J Dermatol; 2016 Aug; 175(2):404-6. PubMed ID: 26972689
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C.
    Leiva-Salinas M; Francés L; Marin-Cabanas I; Arribas Granados MP; Silvestre JF
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):1027-8. PubMed ID: 24629127
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of omalizumab in severe chronic spontaneous urticaria: Real life data from a Greek tertiary center.
    Kyriakou A; Trigoni A; Sotiriadis D; Patsatsi A
    Dermatol Ther; 2018 Nov; 31(6):e12739. PubMed ID: 30194796
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria.
    Nettis E; Cegolon L; Macchia L; Zaza I; Calogiuri G; Di Leo E
    Acta Derm Venereol; 2018 Apr; 98(4):446-448. PubMed ID: 29362811
    [No Abstract]   [Full Text] [Related]  

  • 17. The discovery and development of omalizumab for the treatment of asthma.
    Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
    Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term management of chronic spontaneous urticaria with omalizumab.
    Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
    Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab use during pregnancy for CIU: a tertiary care experience.
    Cuervo-Pardo L; Barcena-Blanch M; Radojicic C
    Eur Ann Allergy Clin Immunol; 2016 Jul; 48(4):145-6. PubMed ID: 27425170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.